Compare NVNO & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVNO | PULM |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.2M |
| IPO Year | 2017 | 2013 |
| Metric | NVNO | PULM |
|---|---|---|
| Price | $6.15 | $1.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 33.8K | 31.9K |
| Earning Date | 10-29-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | N/A | ★ N/A |
| Revenue | $31,243.00 | ★ $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $67.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $0.30 | $1.06 |
| 52 Week High | $13.44 | $4.98 |
| Indicator | NVNO | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 39.26 |
| Support Level | N/A | $1.18 |
| Resistance Level | $11.47 | $1.50 |
| Average True Range (ATR) | 0.59 | 0.15 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 12.16 | 43.00 |
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).